Physician profile
Robert A Abrams
NPI 1437170982
$3,233.21
in general payments reported to CMS, 2019-2025
14 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $342 · 2021: $533 · 2022: $1,010 · 2023: $131 · 2024: $203 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $767.59 | 2019-2025 | Collagenase Santyl |
| Angiodynamics, INC. | $698.46 | 2021-2025 | Auryon Laser System 100-120 Vac |
| Cardiovascular Systems INC. | $383.32 | 2020-2022 | |
| Amgen INC. | $371.82 | 2019-2024 | Krystexxa |
| Bioventus LLC | $215.29 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Melinta Therapeutics, LLC | $209.43 | 2019 | |
| Horizon Therapeutics Plc | $174.72 | 2019-2023 | Krystexxa |
| Abbvie INC. | $168.32 | 2019-2024 | |
| Djo, LLC | $56.99 | 2019-2024 | Aircast, Donjoy, Procare |
| Sebela Pharmaceuticals INC. | $51.69 | 2021-2023 | Naftin |
| Paratek Pharmaceuticals, INC. | $47.56 | 2021-2022 | |
| Nabriva Therapeutics, Plc | $37.42 | 2021-2022 | |
| Kci USA, INC. | $31.70 | 2020-2023 | Activ.A.C., Promogran Prisma |
| Paragon 28, INC. | $18.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.